Cardinal Health Inc. (CAH)
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cardinal Health (CAH) Rises As Market Takes a Dip: Key Facts
In the most recent trading session, Cardinal Health (CAH) closed at $96.71, indicating a +0.91% shift from the previous trading day.
Why the Market Dipped But Cardinal Health (CAH) Gained Today
In the closing of the recent trading day, Cardinal Health (CAH) stood at $95.84, denoting a +0.44% change from the preceding trading day.
Cardinal Health's (CAH) China Syringe Makers Face FDA Warnings
FDA investigations into Cardinal Health's (CAH) China-based syringe manufacturers, Jiangsu Shenli and Jiangsu Caina, reveal significant quality violations, prompting recalls and import alerts.
Why the Market Dipped But Cardinal Health (CAH) Gained Today
Cardinal Health (CAH) closed at $95.97 in the latest trading session, marking a +0.59% move from the prior day.
Cardinal Health (CAH) Stock Sinks As Market Gains: Here's Why
Cardinal Health (CAH) concluded the recent trading session at $93.74, signifying a -0.38% move from its prior day's close.
Reasons to Retain Cardinal Health (CAH) in Your Portfolio Now
Cardinal Health (CAH) gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.
Cardinal Health (CAH) Stock Declines While Market Improves: Some Information for Investors
Cardinal Health (CAH) concluded the recent trading session at $96.01, signifying a -0.9% move from its prior day's close.
Cardinal Health (CAH) Recalls Kits Containing Shenli's Syringes
Cardinal Health (CAH) recalls its procedure kits that contain plastic syringes manufactured by a Chinese manufacturer, Jiangsu Shenli.
Cardinal Health: Growing Into The Valuation
Cardinal Health is a market leader in healthcare with stable revenue streams and growth opportunities, despite being potentially overvalued. Recent performance shows solid revenue and profit growth, but valuation metrics suggest potential overvaluation compared to sector averages. Growth drivers include expansion in specialty pharmaceuticals, biosimilars market, and emerging healthcare segments, with a focus on operational efficiency and customer value propositions.
5 Upcoming Dividend Increases Including A King
This week's increases include Dividend King Sysco Corporation with a 2% increase, extending its 54-year streak. The tables and lists are generated using data from the U.S. Dividend Champions spreadsheet and NASDAQ. I review some companies closer as part of my review process for including them in my own personal portfolio.
5 Cheap Stocks Buying Back Shares at Reasonable Prices
Buybacks are in fashion. But at today's valuations, companies could be paying up for their own stock—and that's never a good idea, whether you're a CEO or a retail investor.
